Navigation Links
As Predicted: Chronic Virus Found Living in Tumors of the Prostate
Date:9/21/2009

ROCHESTER, N.Y., Sept. 21 /PRNewswire/ -- According to Dr. Ila R. Singh, an associate professor of pathology at the University of Utah, "for the first time we have analyzed prostate cancer and normal prostate tissue and found cancers are much more likely to have [the XMRV virus] ... It was also more likely to be present in more aggressive tumors," Singh said. "We found it in 20 percent of the least aggressive tumors and over 45 percent of the most aggressive tumors."

More and more studies find chronic viruses living in tumors, exactly as predicted by Dr. Hanan Polansky in his highly acclaimed 2003 "purple book." According to Dr. Polansky, a chronic virus is a genetic parasite. In high concentrations, the virus "starves" certain human genes and forces them to behave as if they have been mutated, leading to cancer and other diseases.

Think of the nucleus inside the cell as a field with many flowers. To bear fruit, the flowers need pollination by certain bees. Now think of a virus as another flower that migrated into the field. The viral flower also attracts the bees, however with much higher efficiency (stronger scent?). What happens to the production of fruit by the local flowers? It declines. And since many animals are dependent on this fruit, the entire ecosystem is affected. The "starved" human genes stop bearing their fruit, or proteins. They behave as if they've been mutated. (They were not, but to a puzzled scientist they look like they've been mutated!) And without the needed proteins, the cell stops functioning properly, a condition we call disease.

The Starved Gene is a fundamental discovery. It applies to many viruses, many human genes, and many diseases. This discovery inspired scientists at polyDNA to develop a broad-range, all-natural nutritional supplement that targets viruses. To develop the antiviral supplement, they used their signature process. They scanned the scientific literature, analyzed thousands of papers using a proprietary bioinformatics-based computer program, and identified the most effective and safe antiviral natural ingredients. These ingredients were combined to form Gene-Eden, a supplement that targets viruses such as the flu virus, Epstein Barr Virus (EBV), Cytomegalovirus (CMV), Herpes Simplex Virus (HSV), Varicella Zoster Virus(VZV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Papillomavirus (HPV).

For more information on Gene-Eden, visit http://www.gene-eden.com. To order Gene-Eden, visit http://www.Amazon.com.

About Us:

The Center for the Biology of Chronic Disease (http://www.cbcd.net) is a not-for-profit tax-exempt organization under section 501(c)3 of the IRS tax code. The center's mission is to advance the research on the biology of chronic disease and to accelerate the discovery of a cure for these diseases.

To receive our newsletter, please send the contact below an email with "Please add" in the subject. The newsletter includes announcements and explanations of recent scientific discoveries regarding the biology, prevention, and treatment of chronic diseases in everyday terms.

    Contact:

    Tal Davidson
    Phone: 585-200-5546
    Email: tdavidson@cbcd.net

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE The Center for the Biology of Chronic Disease
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
3. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
4. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
5. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
6. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
9. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
10. Move to AMITIZA Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):